TG Therapeutics Inc (NASDAQ:TGTX) to Post Q2 2019 Earnings of ($0.38) Per Share, B. Riley Forecasts

TG Therapeutics Inc (NASDAQ:TGTX) – Equities researchers at B. Riley issued their Q2 2019 earnings estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, June 11th. B. Riley analyst H. Polishetty expects that the biopharmaceutical company will post earnings per share of ($0.38) for the quarter. B. Riley has a “Buy” rating on the stock. B. Riley also issued estimates for TG Therapeutics’ Q3 2019 earnings at ($0.34) EPS, Q4 2019 earnings at ($0.32) EPS, FY2019 earnings at ($1.41) EPS, FY2020 earnings at ($1.26) EPS, FY2021 earnings at ($0.96) EPS, FY2022 earnings at ($0.63) EPS and FY2023 earnings at $0.24 EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. TG Therapeutics had a negative net margin of 99,471.43% and a negative return on equity of 309.17%. The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million.

Several other brokerages have also recently commented on TGTX. BidaskClub upgraded shares of TG Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 5th. Zacks Investment Research cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of TG Therapeutics in a research report on Friday, April 12th. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 price target on shares of TG Therapeutics in a research report on Monday, May 13th. Finally, ValuEngine upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $14.07.

Shares of NASDAQ:TGTX opened at $7.12 on Friday. TG Therapeutics has a one year low of $3.32 and a one year high of $14.65. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.72 and a current ratio of 1.72.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. grew its holdings in TG Therapeutics by 46.5% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,927 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 2,200 shares during the period. Advisor Group Inc. grew its holdings in TG Therapeutics by 23.6% during the first quarter. Advisor Group Inc. now owns 7,850 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,500 shares during the period. LPL Financial LLC acquired a new position in TG Therapeutics during the fourth quarter valued at approximately $49,000. NumerixS Investment Technologies Inc acquired a new position in TG Therapeutics during the fourth quarter valued at approximately $50,000. Finally, BNP Paribas Arbitrage SA grew its holdings in TG Therapeutics by 239.6% during the first quarter. BNP Paribas Arbitrage SA now owns 13,117 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 9,255 shares during the period. Hedge funds and other institutional investors own 54.60% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Read More: Why does a company issue an IPO?

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply